The phase 1, 2, and 3 INFRONT trials evaluate latozinemab (AL001), an immune-modulating recombinant human anti-human monoclonal antibody designed to block and reduce sortilin levels, thereby increasing progranulin levels, which are pathologically reduced in those with an FTD-PGRN mutation. This evidence concerns the gene GRN and frontotemporal dementia.